Synexa Life Sciences to appoint Chief Commercial Officer to support company growth ambitions




  • No categories
  • Leading specialist biomarker and bioanalysis solutions provider further strengthens global management team.

    LEIDEN, THE NETHERLANDS, 19 Aug 2022 – Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis services, announces that Claire Jenkins will be joining the company from 1st December 2022 in the role of Chief Commercial Officer.

    As a member of the global management team, Claire will focus on the commercial strategy of the group and oversee business development, marketing and client services.

    Emile Lens, CEO of Synexa Life Sciences, commented:

    “Claire brings an enormous wealth of experience and expertise in our field, with more than two decades of commercial experience, having worked with large global CROs and smaller, more focused bioanalysis companies. We are extremely happy and proud that she has decided to strengthen our team and we are really looking forward to working with her.”

    About Synexa Life Sciences

    For nearly 20 years Synexa Life Sciences has supported leading biopharma clients across the globe to achieve their clinical milestones through the application of cutting-edge biomarker science. Synexa specialises in the development, validation and delivery of a wide range of complex and custom-designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Synexa is backed by Gilde Healthcare, a leading European healthcare investor managing funds of over €1.9 billion. 

    For further information please contact:

    Emile Lens 


    Talk to our Biomarker Experts